-
摘要: 目的:探讨髓样分化因子88(MyD88)在喉癌组织中的表达及临床意义。方法:收集喉癌患者51例,所有患者术后均经病理诊断结果证实,通过免疫组织化学方法检测MyD88蛋白在喉癌及其癌旁组织中的表达,并探讨MyD88表达量与临床病理特征和患者预后的相关性。结果:MyD88在喉癌组织中阳性表达率为68.6%,明显高于癌旁正常组织中的阳性表达率11.8%(P<0.01);MyD88的阳性表达率与喉癌患者的年龄、性别、分化程度和肿瘤部位无关(P>0.05),与临床分期(P<0.01)和淋巴结转移(P<0.05)呈正相关。MyD88的表达量与患者的5年生存率呈反比,高表达MyD88的患者5年生存率显著低于低表达者(P<0.05)。结论:MyD88可能是喉癌发病机制中的重要参与者,靶向MyD88的治疗有可能改善喉癌患者的预后。Abstract: Objective: To investigate the myeloid differentiation factor 88 (MyD88) expression in laryngeal carcinoma and its clinical significance.Method: Fifty-one patients with laryngeal carcinoma were collected,and all patients were confirmed by pathological diagnosis results. The expression of MyD88 protein was detected by immunohistochemical method in laryngeal cancer and its adjacent tissues to investigate the correlation among MyD88 expression,clinicopathological characteristics and prognosis of patients.Result: The positive expression rate of MyD88 in laryngeal cancer tissues was 68.6%, significantly higher than that in normal tissues adjacent to carcinoma of which positive expression rate was 11.8%; MyD88 positive rate had nothing to do with laryngeal cancer patients age, sex, differentiation and tumour location (all P>0.05), but correlated with clinical stage (P<0.01) and lymph node metastasis (P<0.05). In addition, the study also found that the expression of MyD88 quantity was inversely proportional with the five-year survival rate. The survival rate of patients with higher expression of MyD88 was significantly lower than that of patients with lower expression(P<0.05).Conclusion: MyD88 may be an important participant in the pathogenesis of laryngeal carcinoma, MyD88 targeted therapy may improve the prognosis of patients with laryngeal cancer.
-
-
[1] 胡尚英,陈万青, 赵方辉,等.中国2003-2007年口腔和咽喉癌发病与死亡分析[J]. 中华流行病学杂志,2013,34(2):164-167.
[2] FOCHT K L,MARTIN-HARRIS B,BONILHA H S. Stroboscopic Parameters Reported as Voice Outcome Measures in Patients Treated for Laryngeal Cancer: A Systematic Review[J]. J Med Speech Lang Pathol, 2013,21:5-5.
[3] KFOURY A,VIRARD F, RENNO T, et al. Dual function of MyD88 in inflammation and oncogenesis: implications for therapeutic intervention[J]. Curr Opin Oncol,2014,26:86-91.
[4] 马丹,满晓华,高军,等. 胰腺癌组织Shh、Gli1、Sufu、TAK1、p-TAK1蛋白的表达及其临床意义[J]. 中华胰腺病杂志,2013,13(4):240-243.
[5] STARSKA K, FORMA E,LEWY-TRENDA I,et al. The expression of SOCS1 and TLR4-NFkappaB pathway molecules in neoplastic cells as potential biomarker for the aggressive tumor phenotype in laryngeal carcinoma[J]. Folia Histochem Cytobiol,2009,47:401-410.
[6] YOSHIDA K,SASAKI R, NISHIMURA H,et al. Nuclear factor-kappaB expression as a novel marker of radioresistance in early-stage laryngeal cancer[J]. Head Neck,2010,32:646-655.
[7] HUANG C,HUANG K,WANG C, et al. Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis[J]. Oncol Rep,2009,22:89-95.
[8] WANG J Q,JEELALL Y S,FERGUSON L L, et al. Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation[J]. Front Immunol,2014,5:367-367.
[9] BEG A A,FINCO T S,NANTERMET P V,et al. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation[J]. Mol Cell Biol,1993,13:3301-3310.
[10] KFOURY A, VIRARD F, RENNO T, et al. Dual function of MyD88 in inflammation and oncogenesis: implications for therapeutic intervention[J]. Curr Opin Oncol,2014,26:86-91.
[11] LOIARRO M,RUGGIERO V,SETTE C. Targeting the Toll-like receptor/interleukin 1 receptor pathway in human diseases: rational design of MyD88 inhibitors[J]. Clin Lymphoma Myeloma Leuk, 2013,13:222-226.
-
计量
- 文章访问数: 150
- PDF下载数: 124
- 施引文献: 0
下载: